6th Neuropsychiatric Drug Development Summit

The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D

2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum, with notable approvals on the horizon, as unmet needs in PTSD, bipolar, anxiety, schizophrenia, depression, and ADHD become greater and greater. There is, therefore, a huge deal of novel and promising research to be discussed this October at the 6^th Neuropsychiatric Drug Development Summit.

With discovery, preclinical, translational, and clinical scientists from the likes of Biogen, Otsuka, AbbVie, Genentech, Lundbeck, Delix Therapeutics, Atai, Gilgamesh, and Cerevel Therapeutics, don’t miss the field’s favorite conference, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic.

To know more visit: https://ter.li/sar413